Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in the United Kingdom

被引：14

作者：

Burn, Edward ^{[1
,2
]}

Li, Xintong ^{[2
]}

Delmestri, Antonella ^{[2
]}

Jones, Nathan ^{[2
]}

Duarte-Salles, Talita ^{[1
]}

Reyes, Carlen ^{[1
]}

Martinez-Hernandez, Eugenia ^{[3
,4
]}

Marti, Edelmira ^{[5
]}

Verhamme, Katia M. C. ^{[6
]}

Rijnbeek, Peter R. ^{[6
]}

Strauss, Victoria Y. ^{[2
]}

Prieto-Alhambra, Daniel ^{[2
,6
]}

机构：

[1] Fundacio Inst Univ Recerca Atencio Primaria Salut, Barcelona, Spain

[2] Univ Oxford, Ctr Stat Med CSM, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England

[3] Hosp Clin Barcelona, Dept Neurol, Barcelona, Spain

[4] Univ Barcelona, Barcelona, Spain

[5] Hosp Clin Univ Valencia, Hematol Dept, Hemostasis & Thrombosis Unit, Valencia, Spain

[6] Erasmus MC, Dept Med Informat, Rotterdam, Netherlands

来源：

NATURE COMMUNICATIONS | 2022年 / 13卷 / 01期

关键词：

IMMUNE; IMMUNIZATION; PURPURA;

D O I：

10.1038/s41467-022-34668-w

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Population-based studies can provide important evidence on the safety of COVID-19 vaccines. Using data from the United Kingdom, here we compare observed rates of thrombosis and thrombocytopenia following vaccination against SARS-CoV-2 and infection with SARS-CoV-2 with background (expected) rates in the general population. First and second dose cohorts for ChAdOx1 or BNT162b2 between 8 December 2020 and 2 May 2021 in the United Kingdom were identified. A further cohort consisted of people with no prior COVID-19 vaccination who were infected with SARS-Cov-2 identified by a first positive PCR test between 1 September 2020 and 2 May 2021. The fourth general population cohort for background rates included those people in the database as of 1 January 2017. In total, we included 3,768,517 ChAdOx1 and 1,832,841 BNT162b2 vaccinees, 401,691 people infected with SARS-CoV-2, and 9,414,403 people from the general population. An increased risk of venous thromboembolism was seen after first dose of ChAdOx1 (standardized incidence ratio: 1.12 [95% CI: 1.05 to 1.20]), BNT162b2 (1.12 [1.03 to 1.21]), and positive PCR test (7.27 [6.86 to 7.72]). Rates of cerebral venous sinus thrombosis were higher than otherwise expected after first dose of ChAdOx1 (4.14 [2.54 to 6.76]) and a SARS-CoV-2 PCR positive test (3.74 [1.56 to 8.98]). Rates of arterial thromboembolism after vaccination were no higher than expected but were increased after a SARS-CoV-2 PCR positive test (1.39 [1.21 to 1.61]). Rates of venous thromboembolism with thrombocytopenia were higher than expected after a SARS-CoV-2 PCR positive test (5.76 [3.19 to 10.40]). Population-based studies can provide information on the safety of COVID-19 vaccines. Here the authors report the rates thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in the United Kingdom and compare them with the background (expected) rates in the general population.

引用

页数：10